NZ’s Smoking Revolution: Lancet Study Points to Possible Lessons for India

Using joinpoint regression analysisa statistical method that identifies the precise point in time when a trend changes direction and measures how sharply it shiftsresearchers confirmed a five‑fold acceleration in decline, from 3.5% to 17.9% annually. For India, home to 13.5 crore smokers and carrying one of the world’s heaviest tobacco‑related health burdens, the findings provide a timely evidence‑based reference point.

Dr Saurabh Tomar, MBBS, MD Pulmonary Medicine,Interventional Pulmonologist, Aakash Healthcare, Dwarka, New Delhi, notes,“The Lancet study confirms what clinicians observe: conventional tobacco control has a ceiling effect. Despite New Zealand’s full WHO toolkit plain packaging, graphic warnings,and a decade of excise hikes smoking declined only gradually. The structural shift came when regulated, substantially less harmful nicotine alternatives were recognised as cessation tools and made accessible to adults in 2018/19. Science shows it is tobacco combustion, not nicotine, that produces 7,000+ chemicals causing lung cancer, COPD, and cardiovascular disease. India’s policy must reflect this distinction.”

New Zealand’s experience shows how adult smoking reduction can be achieved alongside youth protection — a balance often debated in India’s regulatory discourse. After tightening rules with age limits (18 years), flavour restrictions, bans on disposables, and nicotine caps, youth daily smoking among 14–15-year-oldscontinued to fall to historic lows, even as youth vaping prevalence rose. The Lancet authors stress that adult declines occurred without reversing youth smoking trends, affirming that nicotine itself is not the cause of disease — combustion is.

Dr Satish Kumar Sr Consultant Internal Medicine Pacific One Health Hospital New Delhi, says, “While India and New Zealand differ in geography and health systems, the epidemiology of tobacco dependence and nicotine pharmacology are universal. The Lancet study shows conventional demand‑reduction policies, though necessary, are insufficient for rapid declines, especially among disadvantaged groups. New Zealand’s data demonstrates that changevia regulated access to substantially less harmful nicotine alternatives complemented traditional measures and accelerated progress where decades yielded only incremental gains. India’s 13.5 lakh annual tobacco deathsare a policy variable, not a fixed number.”

The Lancet study highlights a vital distinction often blurred in tobacco policy: reducing harm from combustible tobacco versus eliminating nicotine. These are separate goals requiring different frameworks, and India risks limiting cessation outcomes by conflating them. Since 2009, the WHO has listed nicotine replacement therapies on its Essential Medicines List, while India’s DTAB exempted 2mg nicotine gum under Schedule K— affirming that combustion, not nicotine, causes disease.

As India confronts 13.5 crore smokers with unassisted quit rates below 4% and under‑resourced cessation support, the Lancet‑documented New Zealand experience offers evidence‑led, equity‑focused framework. The same statistical method that pinpoints exactly when and how sharply a national trend changes confirmed that harm reduction, through regulated access to substantially less harmful nicotine alternatives, can complement and accelerate what conventional tobacco control alone has struggled to achieve.